Discloseable transaction - investment in a limited partnership
Filed with HKEX · · 10 pages · English
Summary by 6ix AI
Dawnrays Pharmaceutical Holdings Ltd. has announced a discloseable transaction regarding an investment in a limited partnership, where its subsidiary Suzhou Dawnrays will invest a significant amount as a limited partner. The partnership aims to focus on equity investments primarily in the pharmaceutical, biotechnology, and healthcare sectors to achieve favorable returns. This transaction is subject to reporting requirements but does not require shareholder approval under the relevant listing rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Dawnrays Pharmaceutical Holdings Ltd. on 6ix
Earlier from Dawnrays Pharmaceutical
- Dawnrays Pharmaceutical Holdings: Proposals for general mandates to issue and repurchase shares; re-election of directors and notice of annual general meeting
- Next Day Disclosure Return
- Dawnrays Pharmaceutical Holdings: Supplemental announcement in relation to 2019 annual report
- Discloseable transaction-construction agreements
- Announcement of Interim Results for the six months ended 30 June 2017
Later from Dawnrays Pharmaceutical
- 2026 Interim report
- Notification letter and reply form to registered shareholders - notice of publication of 2026 interim report
- Notification letter and request form to non-registered holder - notice of publication of 2026 interim report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (Revised) Next Day Disclosure Return
Follow Dawnrays Pharmaceutical into a list and get an email when it puts out news.
Follow Dawnrays Pharmaceutical